Journal
European journal of nuclear medicine and molecular imaging
Publication Date
1-1-2022
Volume
49
Issue
2
First Page
550
Last Page
562
Document Type
Open Access Publication
DOI
10.1007/s00259-021-05489-8
Rights and Permissions
Roy, S., Whitehead, T.D., Li, S. et al. Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging 49, 550–562 (2022). https://doi.org/10.1007/s00259-021-05489-8. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Roy, Sudipta; Whitehead, Timothy D; Li, Shunqiang; Ademuyiwa, Foluso O; Wahl, Richard L; Dehdashti, Farrokh; and Shoghi, Kooresh I, "Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer." European journal of nuclear medicine and molecular imaging. 49, 2. 550 - 562. (2022).
https://digitalcommons.wustl.edu/oa_4/3052
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
